MarketInOut Stock Screener Log In | Sign Up
 

Actuate Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/18/2026
Actuate Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization23.95 mln
Float10.56 mln
Earnings Date11/13/2026

Piotroski F-Score

4 / 9
Borderline

1-Year Forecast

11.68
Transformational upside

Relative Strength

2 / 100
Severely lagging

Debt / Equity

0.41
Low leverage

ROE

-487
Deeply negative

ROA

-194
Deeply negative

Business Description

Actuate Therapeutics is a Fort Worth, Texas-based company focused on developing new cancer treatments. Its main drug, elraglusib, is currently being tested in clinical trials for several difficult-to-treat cancers, including advanced pancreatic cancer and certain childhood cancers such as Ewing sarcoma, neuroblastoma, and pediatric leukemias. The company was founded in 2015 and has been building its research pipeline with the goal of bringing more effective options to patients with limited treatment choices.

Key Fundamentals

EPS-0.87
ROE-487
ROIC-1,766
ROA-194
Interest Cover-1,026
EBITDA, mln-20.43
EV / EBITDA-2.27
EV / EBIT-2.27

Quote Details

Last 0.9812
Change -0.014 (-1.41%)
Open 1.00
Volume 113,077
Turnover 110,951
Average Volume 476,696

Financial Ratios

Leverage Ratio5.26
Current Ratio1.25
Price / Book40.37
Price / Tangible Book41.38
Debt / Equity0.41

Financial Strength

Piotroski F-Score 4 / 9
1-Year Target Price11.68
Short Ratio2.89
Short % of Float11.10

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -8.3% 9 / 100   
1 Month -7.43% 25 / 100   
2 Months -50.69% 6 / 100   
6 Months -60.75% 6 / 100   
1 Year -85.82% 6 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us